Erin M Warshaw

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/563349/publications.pdf

Version: 2024-02-01

289 papers 8,642 citations

51 h-index 80 g-index

291 all docs

291 docs citations

times ranked

291

4725 citing authors

#	Article	IF	CITATIONS
1	Occupational contact dermatitis: Retrospective analysis of North American Contact Dermatitis Group Data, 2001 to 2016. Journal of the American Academy of Dermatology, 2022, 86, 782-790.	0.6	16
2	Patch Testing to Carvone: North American Contact Dermatitis Group Experience, 2009 to 2018. Dermatitis, 2022, 33, 42-50.	0.8	5
3	Contact Allergens in Prescription Topical Ophthalmic Medications. Dermatitis, 2022, 33, 135-143.	0.8	2
4	Contact Dermatitis Associated With Hair Care Products: A Retrospective Analysis of the North American Contact Dermatitis Group Data, 2001–2016. Dermatitis, 2022, 33, 91-102.	0.8	12
5	Age-related differences in patch testing results among children: Analysis of North American Contact Dermatitis Group Data, 2001-2018. Journal of the American Academy of Dermatology, 2022, 86, 818-826.	0.6	7
6	Patch testing with ammonium persulfate: The North American Contact Dermatitis Group Experience, 2015-2018. Journal of the American Academy of Dermatology, 2022, 87, 1014-1023.	0.6	6
7	Patch Test Reactions Associated With Topical Medications: A Retrospective Analysis of the North American Contact Dermatitis Group Data (2001–2018). Dermatitis, 2022, 33, 144-154.	0.8	2
8	Photopatch test results of the North American contact dermatitis group, 1999â€2009. Photodermatology Photoimmunology and Photomedicine, 2022, 38, 288-291.	0.7	9
9	Prevalence and trend of allergen sensitization in patients with a diagnosis of stasis dermatitis referred for patch testing, North American contact dermatitis group data, 2001–2016. Archives of Dermatological Research, 2022, 314, 857-867.	1.1	7
10	Shoe Allergens: A Retrospective Analysis of Cross-sectional Data From the North American Contact Dermatitis Group, 2005–2018. Dermatitis, 2022, 33, 62-69.	0.8	3
11	Occupational Contact Dermatitis in Dental Personnel: A Retrospective Analysis of the North American Contact Dermatitis Group Data, 2001 to 2018. Dermatitis, 2022, 33, 80-90.	0.8	6
12	Allergic contact dermatitis from dipropylene glycol in hydrocortisone lotion. Contact Dermatitis, 2022, 87, 112-114.	0.8	1
13	Medical adhesive allergens: Retrospective analysis of cross-sectional data from the North American Contact Dermatitis Group, 2001-2018. Journal of the American Academy of Dermatology, 2022, 87, 1024-1032.	0.6	6
14	Patch testing with glucosides: The North American Contact Dermatitis Group experience, 2009-2018. Journal of the American Academy of Dermatology, 2022, 87, 1033-1041.	0.6	4
15	Patch testing with cobalt in children and adolescents: North American contact dermatitis group experience, 2001–2018. Contact Dermatitis, 2022, 87, 420-429.	0.8	2
16	Contact dermatitis to personal care products is increasing (but different!) in males and females: North American Contact Dermatitis Group data, 1996-2016. Journal of the American Academy of Dermatology, 2021, 85, 1446-1455.	0.6	16
17	Eyelid dermatitis in patients referred for patch testing: Retrospective analysis of North American Contact Dermatitis Group data, 1994-2016. Journal of the American Academy of Dermatology, 2021, 84, 953-964.	0.6	16
18	Scalp involvement in patients referred for patch testing: Retrospective cross-sectional analysis of North American Contact Dermatitis Group data, 1996 to 2016. Journal of the American Academy of Dermatology, 2021, 84, 977-988.	0.6	6

#	Article	IF	Citations
19	Hand dermatitis in adults referred for patch testing: Analysis of North American Contact Dermatitis Group Data, 2000 to 2016. Journal of the American Academy of Dermatology, 2021, 84, 989-999.	0.6	8
20	Currently relevant p-phenylenediamine patch test reactions associated with hair dye and nonscalp anatomic areas: Retrospective cross-sectional analysis of North American Contact Dermatitis Group data, 2001 to 2016. Journal of the American Academy of Dermatology, 2021, 84, e175-e177.	0.6	1
21	Patch Testing With Carmine 2.5% in Petrolatum by the North American Contact Dermatitis Group, 2011–2012. Dermatitis, 2021, 32, 94-100.	0.8	2
22	Contact dermatitis from an azelaic acidâ€containing gel. Contact Dermatitis, 2021, 85, 101-102.	0.8	1
23	Methylisothiazolinone in "dermatologyâ€recommended―sunscreens: An important mimicker of photoallergic contact dermatitis. Photodermatology Photoimmunology and Photomedicine, 2021, 37, 366-370.	0.7	0
24	North American Contact Dermatitis Group Patch Test Results: 2017–2018. Dermatitis, 2021, 32, 111-123.	0.8	78
25	Prevalence and trend of allergen sensitization in patients with nummular (discoid) eczema referred for patch testing: North American Contact Dermatitis Group data, 2001–2016. Contact Dermatitis, 2021, 85, 46-57.	0.8	6
26	Prevalence and Trend of Allergen Sensitization in Adults and Children with Atopic Dermatitis Referred for Patch Testing, North American Contact Dermatitis Group Data, 2001-2016. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2853-2866.e14.	2.0	9
27	Hand eczema in children referred for patch testing: North American Contact Dermatitis Group Data, 2000–2016*. British Journal of Dermatology, 2021, 185, 185-194.	1.4	5
28	Patch Testing to Methyldibromoglutaronitrile/Phenoxyethanol: North American Contact Dermatitis Group Experience, 1994–2018. Dermatitis, 2021, 32, 256-266.	0.8	2
29	Patch testing with sodium disulfite: North American Contact Dermatitis Group experience, 2017 to 2018. Contact Dermatitis, 2021, 85, 285-296.	0.8	7
30	Contact dermatitis in music professionals referred for patch testing: North <scp>American</scp> Contact Dermatitis Group data, 1996–2018. Contact Dermatitis, 2021, 85, 359-362.	0.8	0
31	Contact dermatitis associated with preservatives: Retrospective analysis of North American Contact Dermatitis Group data, 1994 through 2016. Journal of the American Academy of Dermatology, 2021, 84, 965-976.	0.6	17
32	Interâ€rater variability in patch test readings and final interpretation using storeâ€forward teledermatology. Contact Dermatitis, 2021, 85, 274-284.	0.8	6
33	Prevalence and trend of allergen sensitization in patients referred for patch testing with a final diagnosis of psoriasis: <scp>N</scp> orth <scp>A</scp> merican <scp>C</scp> ontact <scp>D</scp> ermatitis <scp>G</scp> roup data, 2001â€2016. Contact Dermatitis, 2021, 85, 435-445.	0.8	3
34	Men's Facial Moisturizers in the Metrosexual Era. Dermatitis, 2021, 32, 185-194.	0.8	3
35	Allergic contact dermatitis due to polyvinylpyrrolidone (<scp>PVP</scp>)/eicosene copolymer. Contact Dermatitis, 2021, 85, 458-460.	0.8	2
36	It is Easy Being Green and Low Allergen! Hypoallergenic and Environment-Friendly Laundry Detergents and Travel Hand Soaps. Dermatitis, 2021, 32, e166-e169.	0.8	1

#	Article	IF	Citations
37	Contact Dermatitis Associated With Musical Instruments. Dermatitis, 2021, Publish Ahead of Print, e156-e158.	0.8	O
38	Trends in Patch Testing in the Medicare Part B Fee-for-Service Population. Dermatitis, 2021, Publish Ahead of Print, .	0.8	1
39	Contact Allergy in Canada Versus United States. Dermatitis, 2021, Publish Ahead of Print, 421-429.	0.8	1
40	A Cautionary Tale. Dermatitis, 2021, Publish Ahead of Print, e117-e119.	0.8	0
41	Patients with patch test reactions associated with eye care products: Retrospective analysis of <scp>N</scp> orth <scp>A</scp> merican contact dermatitis group data, <scp>2001</scp> â€ <scp>2018</scp> . Contact Dermatitis, 2021, 85, 712-715.	0.8	2
42	Prevalence and Trend of Allergen Sensitization in Patients with a Diagnosis of Seborrheic Dermatitis After Patch Testing, North American Contact Dermatitis Group Data, 2001-2016. Journal of the American Academy of Dermatology, 2021, , .	0.6	0
43	Patch Testing to Ethylhexylglycerin. Dermatitis, 2021, Publish Ahead of Print, .	0.8	0
44	Patch Testing With Tocopherol and Tocopherol Acetate: The North American Contact Dermatitis Group Experience, 2001 to 2016. Dermatitis, 2021, 32, 308-318.	0.8	3
45	Fragrance- and Botanical-Related Allergy and Associated Concomitant Reactions: A Retrospective Analysis of the North American Contact Dermatitis Group Data 2007–2016. Dermatitis, 2021, 32, 42-52.	0.8	15
46	Formaldehyde Release From Predispersed Tattoo Inks: Analysis Using the Chromotropic Acid Method. Dermatitis, 2021, 32, 327-332.	0.8	5
47	Isothiazolinone Detection in Dish Soap and Personal Care Products: Comparison of Lovibond Isothiazolinone Test Kit and Ultrahigh-Performance Liquid Chromatography–Tandem Mass Spectrometry. Dermatitis, 2021, 32, 245-250.	0.8	2
48	Allergic Contact Dermatitis to Pramoxine (Pramocaine). Dermatitis, 2021, 32, 32-37.	0.8	1
49	Positive Patch Test Reactions to Carba Mix and Thiuram Mix: The North American Contact Dermatitis Group Experience (1994–2016). Dermatitis, 2021, 32, 173-184.	0.8	7
50	Our Approach to Textile Dermatitis: In-Clinic Dye Extraction. Dermatitis, 2021, 32, e14-e15.	0.8	2
51	Patch Testing of Mercaptobenzothiazole and Mercapto Mix: The North American Contact Dermatitis Group Experience, 1994–2016. Dermatitis, 2021, 32, 232-244.	0.8	2
52	A Mini-epidemic of Suspected Contact Dermatitis to Delta Airlines Uniforms. Dermatitis, 2021, 32, e69-e71.	0.8	0
53	Patch Testing: The Patient Experience. Dermatitis, 2021, 32, 333-338.	0.8	0
54	Importance of Supplemental Patch Testing Beyond a Screening Series for Patients With Dermatitis. JAMA Dermatology, 2021, 157, 1456.	2.0	5

#	Article	IF	Citations
55	Killing Two Birds With One Bar: Shampoo and Conditioner Bars Are Low Allergen and Environmentally Friendly. Dermatitis, 2021, 32, e60-e64.	0.8	О
56	Patch Test Reactions Associated With Nontopical Medications: A Retrospective Analysis of North American Contact Dermatitis Group Data, 2001–2018. Dermatitis, 2021, 32, e127-e129.	0.8	1
57	Characterization of Tattoo Aftercare Products: Allergenic Ingredients and Marketing Claims. Dermatitis, 2021, 32, 301-307.	0.8	4
58	Acrylates: new sources and new allergens. Clinical and Experimental Dermatology, 2020, 45, 277-283.	0.6	32
59	Allergic reactions to tattoos: Retrospective analysis of North American Contact Dermatitis Group data, 2001-2016. Journal of the American Academy of Dermatology, 2020, 82, e61-e62.	0.6	6
60	Axillary allergic contact dermatitis to topical clindamycin. Contact Dermatitis, 2020, 82, 313-314.	0.8	3
61	Prescription-strength topical corticosteroids available over the counter: Cross-sectional study of 80 stores in 13 United States cities. Journal of the American Academy of Dermatology, 2020, 82, 524-525.	0.6	3
62	Facial Dermatitis in Male Patients Referred for Patch Testing. JAMA Dermatology, 2020, 156, 79.	2.0	16
63	Evaluation of Patch Test Findings in Patients With Anogenital Dermatitis. JAMA Dermatology, 2020, 156, 85.	2.0	11
64	Do it Yourself Without Allergic Contact Dermatitis: Safe Household Cleaning Product Alternatives. Dermatitis, 2020, 31, e16-e17.	0.8	0
65	American Contact Dermatitis Society Core Allergen Series: 2020 Update. Dermatitis, 2020, 31, 279-282.	0.8	40
66	Summertime Dermatitis: When the Repellent Is the Culprit, Not the Bugs!. Dermatitis, 2020, 31, e30-e32.	0.8	2
67	Navigating Tattoo-Related Allergic Dermatitis: Beyond Pigments. Dermatitis, 2020, 31, e59-e60.	0.8	2
68	Contact Dermatitis Associated With Nail Care Products: Retrospective Analysis of North American Contact Dermatitis Group Data, 2001–2016. Dermatitis, 2020, 31, 191-201.	0.8	19
69	Tolerability of hair cleansing conditioners: a double-blind randomized, controlled trial designed to evaluate consumer complaints to the U.S. Food and Drug Administration. Cutaneous and Ocular Toxicology, 2020, 39, 89-96.	0.5	4
70	Methylisothiazolinone in children's nail polish. Pediatric Dermatology, 2020, 37, 745-747.	0.5	8
71	Safety Checks in Patch Clinic: 5 Hurdles in the Patch Testing Obstacle Course. Dermatitis, 2020, 31, 89-98.	0.8	3
72	Relevant Contact Allergy to Benzisothiazolinone in a Personal Care Product. Dermatitis, 2020, 31, e13-e14.	0.8	7

#	Article	IF	Citations
73	Chemical Identification and Confirmation of Contact Allergens. Dermatitis, 2020, 31, 99-105.	0.8	5
74	Patch Testing to Diphenylguanidine by the North American Contact Dermatitis Group (2013–2016). Dermatitis, 2020, 31, 350-358.	0.8	2
75	Cutaneous Reactions to Aluminum. Dermatitis, 2020, 31, 335-349.	0.8	11
76	Clogs Are a Fashionable Option in Cases of Shoe Contact Dermatitis. Dermatitis, 2020, 31, e42-e45.	0.8	0
77	Hold the spice: Allergy to garlic and sulfitesâ€"Possible relevance in a patient with cheilitis granulomatosa. Contact Dermatitis, 2019, 81, 397-398.	0.8	7
78	Reply to: "Response to:  Patients with negative patch tests: Retrospective analysis of North American Contact Dermatitis Group (NACDG) data 2001-2016'― Journal of the American Academy of Dermatology, 2019, 81, e181.	0.6	0
79	Parabens. Dermatitis, 2019, 30, 3-31.	0.8	105
80	Patients with negative patch tests: Retrospective analysis of North American Contact Dermatitis Group (NACDG) data 2001-2016. Journal of the American Academy of Dermatology, 2019, 80, 1618-1629.	0.6	11
81	Pigments in American tattoo inks and their propensity to elicit allergic contact dermatitis. Journal of the American Academy of Dermatology, 2019, 81, 379-385.	0.6	26
82	Safety equipment: When protection becomes a problem. Contact Dermatitis, 2019, 81, 130-132.	0.8	20
83	Genital dermatitis in a transgender patient returning from Thailand: A diagnostic challenge. Travel Medicine and Infectious Disease, 2019, 27, 134-135.	1.5	5
84	Epidemiology of nickel sensitivity: Retrospective cross-sectional analysis of North American Contact Dermatitis Group data 1994-2014. Journal of the American Academy of Dermatology, 2019, 80, 701-713.	0.6	25
85	Formaldehyde Release From Personal Care Products: Chromotropic Acid Method Analysis. Dermatitis, 2019, 30, 67-73.	0.8	20
86	Formaldehyde Release From Clothing and Upholstery Fabrics Using the Chromotropic Acid Method. Dermatitis, 2019, 30, 255-258.	0.8	5
87	Allergic Contact Dermatitis to Crisaborole. Dermatitis, 2019, 30, 272-274.	0.8	5
88	Allergic Contact Dermatitis to Licorice Root Extract. Dermatitis, 2019, 30, 227-228.	0.8	8
89	Isothiazolinone Content of US Consumer Adhesives: Ultrahigh-Performance Liquid Chromatographic Mass Spectrometry Analysis. Dermatitis, 2019, 30, 129-134.	0.8	17
90	Skin Sensitization Induction Risk Assessment of Common Ingredients in Commercially Available Cleansing Conditioners. Dermatitis, 2019, 30, 116-128.	0.8	7

#	Article	IF	Citations
91	Allergic Contact Dermatitis to a Self-adherent Bandage Wrap in a Formaldehyde-allergic Patient. Dermatitis, 2019, 30, 169-170.	0.8	2
92	Oh My Glucosides! Occult Sources in Medical Products. Dermatitis, 2019, 30, 228-230.	0.8	6
93	Allergic Dermatitis to Dyclonine (Dyclocaine). Dermatitis, 2019, 30, 372-373.	0.8	3
94	Alternatives for Allergens in the 2018 American Contact Dermatitis Society Core Series: Report by the American Contact Alternatives Group. Dermatitis, 2019, 30, 87-105.	0.8	15
95	Formaldehyde Release From Baby Wipes: Analysis Using the Chromotropic Acid Method. Dermatitis, 2019, 30, 207-212.	0.8	12
96	Occupationally Related Nickel Reactions: A Retrospective Analysis of the North American Contact Dermatitis Group Data 1998–2016. Dermatitis, 2019, 30, 306-313.	0.8	15
97	Airborne Allergic Contact Dermatitis: Management and Responsible Allergens on the American Contact Dermatitis Society Core Series. Dermatitis, 2019, 30, 106-115.	0.8	17
98	Allergic contact dermatitis caused by mupirocin and pimecrolimus. Contact Dermatitis, 2019, 80, 132-133.	0.8	11
99	Allergic contact dermatitis to slime: The epidemic of isothiazolinone allergy encompasses school glue. Pediatric Dermatology, 2019, 36, e37-e38.	0.5	24
100	Use of essential oils: A general population survey. Contact Dermatitis, 2019, 80, 391-393.	0.8	19
101	Pet Consort Dermatitis: The Importance of Asking About Pets. Dermatitis, 2018, 29, 45-46.	0.8	7
102	Survey of Patch Test Business Models in the United States by the American Contact Dermatitis Society. Dermatitis, 2018, 29, 85-88.	0.8	5
103	Epidemiology of pediatric nickel sensitivity: Retrospective review of North American Contact Dermatitis Group (NACDG) data 1994-2014. Journal of the American Academy of Dermatology, 2018, 79, 664-671.	0.6	34
104	The Medical Necessity of Comprehensive Patch Testing. Dermatitis, 2018, 29, 107-111.	0.8	19
105	Contact Dermatitis Associated With Skin Cleansers: Retrospective Analysis of North American Contact Dermatitis Group Data 2000–2014. Dermatitis, 2018, 29, 32-42.	0.8	19
106	Chemoprevention of Basal and Squamous Cell Carcinoma With a Single Course of Fluorouracil, 5%, Cream. JAMA Dermatology, 2018, 154, 167.	2.0	93
107	Risk Assessment of the Skin Sensitization Induction Potential of Kathon CG in Rinse-off and Leave-on Personal Care and Cosmetic Products. Dermatitis, 2018, 29, 132-138.	0.8	13
108	Clinically Relevant Reactions to Thimerosal (the "Nonallergenâ€) Exist!. Dermatitis, 2018, 29, 44-45.	0.8	6

#	Article	IF	CITATIONS
109	North American Contact Dermatitis Group Patch Test Results: 2015–2016. Dermatitis, 2018, 29, 297-309.	0.8	230
110	Isothiazolinone in Residential Interior Wall Paint: A High-Performance Liquid Chromatographic–Mass Spectrometry Analysis. Dermatitis, 2018, 29, 332-338.	0.8	20
111	Single question burden of disease assessment in patients referred for patch testing. International Journal of Dermatology, 2018, 57, e136-e138.	0.5	0
112	Allergic contact dermatitis secondary to the use of a bandage impregnated with benzalkonium chloride. Contact Dermatitis, 2018, 79, 387-388.	0.8	10
113	American Contact Dermatitis Society Core Allergen Series: 2017 Update. Dermatitis, 2017, 28, 141-143.	0.8	65
114	Occupational Contact Dermatitis in North American Production Workers Referred for Patch Testing: Retrospective Analysis of Cross-Sectional Data From the North American Contact Dermatitis Group 1998 to 2014. Dermatitis, 2017, 28, 183-194.	0.8	19
115	Wet Wipe Allergens: Retrospective Analysis From the North American Contact Dermatitis Group 2011–2014. Dermatitis, 2017, 28, 64-69.	0.8	21
116	Occupational Contact Dermatitis in North American Print Machine Operators Referred for Patch Testing: Retrospective Analysis of Cross-Sectional Data From the North American Contact Dermatitis Group 1998 to 2014. Dermatitis, 2017, 28, 195-203.	0.8	10
117	Positive Patch-Test Reactions to Essential Oils in Consecutive Patients From North America and Central Europe. Dermatitis, 2017, 28, 246-252.	0.8	35
118	Patch Test Reactions to Corticosteroids: Retrospective Analysis From the North American Contact Dermatitis Group 2007–2014. Dermatitis, 2017, 28, 58-63.	0.8	26
119	Periorbital Allergic Contact Dermatitis Due to Ketotifen. Dermatitis, 2017, 28, 164-165.	0.8	15
120	Allergenic Ingredients in Hand Wet Wipes. Dermatitis, 2017, 28, 329-330.	0.8	1
121	Allergenic Ingredients in Facial Wet Wipes. Dermatitis, 2017, 28, 353-359.	0.8	16
122	Epidemic of Isothiazolinone Allergy in North America: Prevalence Data From the North American Contact Dermatitis Group, 2013–2014. Dermatitis, 2017, 28, 204-209.	0.8	54
123	Allergic Contact Dermatitis From Methylisothiazolinone in Residential Wall Paint. Dermatitis, 2017, 28, 284-287.	0.8	9
124	Occupational Contact Dermatitis in Mechanics and Repairers Referred for Patch Testing: Retrospective Analysis From the North American Contact Dermatitis Group 1998–2014. Dermatitis, 2017, 28, 47-57.	0.8	17
125	The Latest Occult "Hypoallergenic―Allergen: Ethylhexylglycerin. Dermatitis, 2017, 28, 220-222.	0.8	13
126	Allergenic Ingredients in Personal Hygiene Wet Wipes. Dermatitis, 2017, 28, 317-322.	0.8	18

#	Article	IF	CITATIONS
127	Utility of Store and Forward Teledermatology for Skin Patch Test Readings. Dermatitis, 2017, 28, 152-161.	0.8	13
128	Sulfites: No Longer a Zebra?. Dermatitis, 2017, 28, 364-366.	0.8	8
129	Piercing and Metal Sensitivity: Extended Analysis of the North American Contact Dermatitis Group Data, 2007–2014. Dermatitis, 2017, 28, 333-341.	0.8	27
130	North American Contact Dermatitis Group Patch Test Results 2013–2014. Dermatitis, 2017, 28, 33-46.	0.8	171
131	Tobramycin Sensitivity Is Not Consistently Detected by Neomycin on Patch Testing. Dermatitis, 2016, 27, 152-155.	0.8	3
132	Lesions referred to dermatology in the Department of Veterans Affairs (VA) health system: A retrospective chart review. Journal of the American Academy of Dermatology, 2016, 75, 430-434.	0.6	0
133	Epidemiology and Co-Reactivity of Novel Surfactant Allergens: A Double-Blind Randomized Controlled Study. Dermatitis, 2016, 27, 348-354.	0.8	10
134	Vapor Pressure and Predicted Stability of American Contact Dermatitis Society Core Allergens. Dermatitis, 2016, 27, 193-201.	0.8	7
135	Essential Oils: Emerging "Medicaments― Dermatitis, 2016, 27, 227-228.	0.8	5
136	Patch Testing to Essential Oils. Dermatitis, 2016, 27, 382-384.	0.8	4
137	The Association of Race/Ethnicity and Patch Test Results: North American Contact Dermatitis Group, 1998–2006. Dermatitis, 2016, 27, 288-292.	0.8	34
138	Allergic Contact Dermatitis to Ophthalmic Medications: Relevant Allergens and Alternative Testing Methods. Dermatitis, 2016, 27, 333-347.	0.8	32
139	Incidental melanomas detected in veterans referred to dermatology. Journal of the American Academy of Dermatology, 2016, 74, 462-469.	0.6	12
140	A Method for At-Home Lesional Testing for Fixed Drug Eruption. Dermatitis, 2015, 26, 148.	0.8	1
141	Cutaneous Delayed-Type Hypersensitivity to Surfactants. Dermatitis, 2015, 26, 268-270.	0.8	7
142	Protein Contact Dermatitis to Pig Semen. Dermatitis, 2015, 26, 239-240.	0.8	3
143	Sensitivity to Multiple Benzophenone Sunscreen Agents. Dermatitis, 2015, 26, 192-194.	0.8	6
144	Contact Allergy to Surfactants in a Hypoallergenic Liquid Cleanser. Dermatitis, 2015, 26, 284-286.	0.8	12

#	Article	IF	Citations
145	Incidental lesions found in veterans referred to dermatology: The value of a dermatologic examination. Journal of the American Academy of Dermatology, 2015, 72, 651-655.e1.	0.6	21
146	Reliability of store and forward teledermatology for skin neoplasms. Journal of the American Academy of Dermatology, 2015, 72, 426-435.	0.6	71
147	Patch Testing. Journal of the Dermatology Nurses' Association, 2015, 7, 27-29.	0.1	0
148	North American Contact Dermatitis Group Patch Test Results. Dermatitis, 2015, 26, 49-59.	0.8	168
149	Hypersensitivity Reactions to Titanium. Dermatitis, 2015, 26, 7-25.	0.8	48
150	Cost and Utility Analysis of a Store-and-Forward Teledermatology Referral System. JAMA Dermatology, 2015, 151, 1323.	2.0	64
151	Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis. JAMA Dermatology, 2015, 151, 952.	2.0	85
152	Concentrations and stability of methyl methacrylate, glutaraldehyde, formaldehyde and nickel sulfate in commercial patch test allergen preparations. Contact Dermatitis, 2014, 70, 309-315.	0.8	17
153	American Contact Dermatitis Society. Dermatitis, 2014, 25, 39.	0.8	1
154	Adverse Reactions to Sunscreen Agents. Dermatitis, 2014, 25, 289-326.	0.8	78
155	Patch Testing in Children From 2005 to 2012. Dermatitis, 2014, 25, 345-355.	0.8	96
156	Contact Allergy to Pramoxine (Pramocaine). Dermatitis, 2014, 25, 147-148.	0.8	6
157	Body Piercing and Metal Allergic Contact Sensitivity. Dermatitis, 2014, 25, 255-264.	0.8	22
158	Benzophenones. Dermatitis, 2014, 25, 3-10.	0.8	57
159	Allergic contact dermatitis to topical brimonidine tartrate gel 0.33% for treatment of rosacea. Journal of the American Academy of Dermatology, 2014, 71, 832-833.	0.6	18
160	Effect of Store and Forward Teledermatology on Quality of Life. JAMA Dermatology, 2013, 149, 584.	2.0	50
161	Positive Patch Test Reactions to Carba Mix and Iodopropynyl Butylcarbamate. Dermatitis, 2013, 24, 241-245.	0.8	9
162	North American Contact Dermatitis Group Patch Test Results. Dermatitis, 2013, 24, 50-59.	0.8	193

#	Article	IF	CITATIONS
163	Patch Test Reactions Associated With Sunscreen Products and the Importance of Testing to an Expanded Series. Dermatitis, 2013, 24, 176-182.	0.8	43
164	Concomitant Patch Test Reactions to Mercapto Mix and Mercaptobenzothiazole. Dermatitis, 2013, 24, 321-327.	0.8	4
165	Occupationally Related Contact Dermatitis in North American Food Service Workers Referred for Patch Testing, 1994 to 2010. Dermatitis, 2013, 24, 22-28.	0.8	16
166	American Contact Dermatitis Society Core Allergen Series. Dermatitis, 2013, 24, 7-9.	0.8	48
167	North American Contact Dermatitis Group Patch Test Results for 2007–2008. Dermatitis, 2013, 24, 10-21.	0.8	121
168	Clinical Course Outcomes for Store and Forward Teledermatology Versus Conventional Consultation: A Randomized Trial. Journal of Telemedicine and Telecare, 2013, 19, 197-204.	1.4	41
169	Effects of Immunomodulatory Agents on Patch Testing. Dermatitis, 2012, 23, 301-303.	0.8	33
170	Bloodroot. Dermatitis, 2012, 23, 281-283.	0.8	3
171	Occupational Contact Dermatitis in Hairdressers/Cosmetologists. Dermatitis, 2012, 23, 258-268.	0.8	50
172	Melanoma Tumor Seeding After Punch Biopsy. Dermatologic Surgery, 2012, 38, 1083-1085.	0.4	5
173	Positive patch test reactions in older individuals: Retrospective analysis from the North American Contact Dermatitis Group, 1994-2008. Journal of the American Academy of Dermatology, 2012, 66, 229-240.	0.6	62
174	Allergens in the American Contact Dermatitis Society Core Series. Clinics in Dermatology, 2011, 29, 266-272.	0.8	22
175	Is tenderness a reliable predictor for differentiating squamous cell carcinomas from actinic keratoses?. Journal of the American Academy of Dermatology, 2011, 65, 211-212.	0.6	6
176	Teledermatology for diagnosis and management of skin conditions: A systematic review. Journal of the American Academy of Dermatology, 2011, 64, 759-772.e21.	0.6	251
177	Dermatopathology workforce in the United States: AÂsurvey. Journal of the American Academy of Dermatology, 2011, 65, 1180-1185.	0.6	14
178	Cutaneous Reactions to Transdermal Therapeutic Systems. Dermatitis, 2011, 22, 193-203.	0.8	15
179	Allergic Contact Dermatitis from Cetyl Alcohol. Dermatitis, 2011, 22, 56-57.	0.8	16
180	Allergy to Methyldibromoglutaronitrile/Phenoxyethanol (Euxyl K 400): Regulatory Issues, Epidemiology, Clinical Characteristics, and Management. Dermatitis, 2011, 22, 127-140.	0.8	21

#	Article	IF	CITATIONS
181	Association between psoriasis and incident cancer: the Iowa's Women's Health Study. Cancer Causes and Control, 2011, 22, 1003-1010.	0.8	41
182	Melanoma Risk in Relation to Use of Sunscreen or Other Sun Protection Methods. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2583-2593.	1.1	63
183	Allergic Contact Dermatitis from Ethylenediaminetetraacetic Acid. Dermatitis, 2010, 21, 121-122.	0.8	10
184	Allergic Contact Dermatitis from Formaldehyde Textile Resins. Dermatitis, 2010, 21, 65-76.	0.8	40
185	Allergic contact dermatitis caused by durableâ€press finishes does exist in the USA. Contact Dermatitis, 2010, 63, 233-234.	0.8	6
186	Nickel hypersensitivity: a clinical review and call to action. International Journal of Dermatology, 2010, 49, 115-125.	0.5	69
187	Positivity Ratio and Reaction Index: Patch-Test Quality-Control Metrics Applied to the North American Contact Dermatitis Group Database. Dermatitis, 2010, 21, 91-97.	0.8	51
188	Indoor Tanning and Risk of Melanoma: a Case-Control Study in a Highly Exposed Population – Response. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2685-2686.	1.1	2
189	Indoor Tanning and Risk of Melanoma: A Case-Control Study in a Highly Exposed Population. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1557-1568.	1.1	318
190	Interobserver accuracy of store and forward teledermatology for skin neoplasms. Journal of the American Academy of Dermatology, 2010, 62, 513-516.	0.6	15
191	Dermatoscopy use by US dermatologists: A cross-sectional survey. Journal of the American Academy of Dermatology, 2010, 63, 412-419.e2.	0.6	77
192	Accuracy of teledermatology/teledermoscopy and clinic-based dermatology for specific categories of skin neoplasms. Journal of the American Academy of Dermatology, 2010, 63, 348-352.	0.6	33
193	Vulvar Allergic Contact Dermatitis from Clotrimazole. Dermatitis, 2010, 21, 59-60.	0.8	9
194	Positive Patch-Test Reactions to Iodopropynyl Butylcarbamate: Retrospective Analysis of North American Contact Dermatitis Group Data, from 1998 to 2008. Dermatitis, 2010, 21, 303-310.	0.8	19
195	Retapamulin: An Emerging Antimicrobial Allergen. Dermatitis, 2010, 21, 160-161.	0.8	3
196	Vulvar allergic contact dermatitis from clotrimazole. Dermatitis, 2010, 21, 59-60.	0.8	2
197	Allergic patch test reactions associated with cosmetics: Retrospective analysis of cross-sectional data from the North American Contact Dermatitis Group, 2001-2004. Journal of the American Academy of Dermatology, 2009, 60, 23-38.	0.6	87
198	Accuracy of teledermatology for nonpigmented neoplasms. Journal of the American Academy of Dermatology, 2009, 60, 579-588.	0.6	86

#	Article	IF	CITATIONS
199	Accuracy of teledermatology for pigmented neoplasms. Journal of the American Academy of Dermatology, 2009, 61, 753-765.	0.6	146
200	Role of Topical Calcineurin Inhibitors in the Treatment of Seborrheic Dermatitis. American Journal of Clinical Dermatology, 2009, 10, 103-118.	3.3	33
201	Prevention of Nickel Allergy: The Case for Regulation?. Dermatologic Clinics, 2009, 27, 155-161.	1.0	43
202	Teledermatology: A Review of Reliability and Accuracy of Diagnosis and Management. Dermatologic Clinics, 2009, 27, 163-176.	1.0	82
203	Patch-Test Results of the North American Contact Dermatitis Group 2005-2006. Dermatitis, 2009, 20, 149-160.	0.8	233
204	Positive Patch-Test Reactions to Propylene Glycol: A Retrospective Cross-Sectional Analysis from the North American Contact Dermatitis Group, 1996 to 2006. Dermatitis, 2009, 20, 14-20.	0.8	54
205	Positive Patch Test Reactions to Lanolin: Cross-Sectional Data from the North American Contact Dermatitis Group, 1994 to 2006. Dermatitis, 2009, 20, 79-88.	0.8	48
206	The American Contact Dermatitis Society: 20 Years of Progress. Dermatitis, 2009, 20, 303-315.	0.8	3
207	Methylphenidate Patch-Test Protocol and Irritancy Threshold Determination in Healthy Adult Subjects. Dermatitis, 2009, 20, 271-274.	0.8	5
208	Allergic Contact Dermatitis from Retapamulin Ointment. Dermatitis, 2009, 20, 220-221.	0.8	8
209	Plaque-type syringoma: two cases misdiagnosed as microcystic adnexal carcinoma. Journal of Cutaneous Pathology, 2008, 35, 570-574.	0.7	23
210	Allergic contact dermatitis to topical antibiotics: Epidemiology, responsible allergens, and management. Journal of the American Academy of Dermatology, 2008, 58, 1-21.	0.6	134
211	Validity of self-reported nail counts in patients with onychomycosis: A retrospective pilot analysis. Journal of the American Academy of Dermatology, 2008, 58, 136-141.	0.6	3
212	The value of patch testing patients with a scattered generalized distribution of dermatitis: Retrospective cross-sectional analyses of North American Contact Dermatitis Group data, 2001 to 2004. Journal of the American Academy of Dermatology, 2008, 59, 426-431.	0.6	42
213	Solar urticaria. Journal of the American Academy of Dermatology, 2008, 59, 909-920.	0.6	114
214	Practical management of cutaneous reactions to the methylphenidate transdermal system: Recommendations from a dermatology expert panel consensus meeting. Clinical Therapeutics, 2008, 30, 326-337.	1.1	26
215	Contact Allergy: Alternatives for the 2007 North American Contact Dermatitis Group (NACDG) Standard Screening Tray. Disease-a-Month, 2008, 54, 7-156.	0.4	66
216	Sunitinib: A Cause of Bullous Palmoplantar Erythrodysesthesia, Periungual Erythema, and Mucositis. Archives of Dermatology, 2008, 144, 123-5.	1.7	38

#	Article	IF	Citations
217	Contact Allergy in Children Referred for Patch Testing. Archives of Dermatology, 2008, 144, 1329-36.	1.7	140
218	Anogenital Dermatitis in Patients Referred for Patch Testing. Archives of Dermatology, 2008, 144, 749-55.	1.7	53
219	Protein Contact Dermatitis: Allergens, Pathogenesis, and Management. Dermatitis, 2008, 19, 241-251.	0.8	79
220	Patch-Test Reactions to Topical Anesthetics: Retrospective Analysis of Cross-Sectional Data, 2001 to 2004. Dermatitis, 2008, 19, 81-95.	0.8	42
221	Patch-Testing North American Lip Dermatitis Patients: Data from the North American Contact Dermatitis Group, 2001 to 2004. Dermatitis, 2008, 19, 202-208.	0.8	55
222	Lanolin Allergy: History, Epidemiology, Responsible Allergens, and Management. Dermatitis, 2008, 19, 63-72.	0.8	49
223	Contact Dermatitis Associated with Food: Retrospective Cross-Sectional Analysis of North American Contact Dermatitis Group Data, 2001-2004. Dermatitis, 2008, 19, 252-260.	0.8	22
224	Type I Allergy to Insulin: Case Report and Review of Localized and Systemic Reactions to Insulin. Dermatitis, 2008, 19, 52-58.	0.8	7
225	Occupation-Related Contact Dermatitis in North American Health Care Workers Referred for Patch Testing: Cross-Sectional Data, 1998 to 2004. Dermatitis, 2008, 19, 261-274.	0.8	53
226	North American Contact Dermatitis Group Patch-Test Results, 2003-2004 Study Period. Dermatitis, 2008, 19, 129-136.	0.8	99
227	Detection of Nickel Sensitivity Has Increased in North American Patch-Test Patients. Dermatitis, 2008, 19, 16-19.	0.8	69
228	Positive Patch-Test Reactions to Mixed Dialkyl Thioureas: Cross-Sectional Data from the North American Contact Dermatitis Group, 1994 to 2004. Dermatitis, 2008, 19, 190-201.	0.8	23
229	Black-Spot Poison Ivy. Dermatitis, 2008, 19, 48-51.	0.8	5
230	Patch-testing North American lip dermatitis patients: data from the North American Contact Dermatitis Group, 2001 to 2004. Dermatitis, 2008, 19, 202-8.	0.8	5
231	Duct Tape for the Treatment of Common Warts in Adults. Archives of Dermatology, 2007, 143, 309-13.	1.7	63
232	Allergic Contact Cheilitis from Benzophenone-3 in Lip Balm and Fragrance/Flavorings. Dermatitis, 2007, 18, 221-224.	0.8	22
233	Genetics of Nickel Allergic Contact Dermatitis. Dermatitis, 2007, 18, 125-133.	0.8	29
234	Patch Testing for Evaluating Drug Reactions Due to Systemic Antibiotics. Dermatitis, 2007, 18, 63-77.	0.8	15

#	Article	IF	CITATIONS
235	A Double-Blind Randomized Placebo-Controlled Pilot Study Comparing Topical Immunomodulating Agents and Corticosteroids for Treatment of Experimentally Induced Nickel Contact Dermatitis. Dermatitis, 2007, 18, 26-31.	0.8	19
236	Common Contact Allergens Associated with Eyelid Dermatitis: Data from the North American Contact Dermatitis Group 2003-2004 Study Period. Dermatitis, 2007, 18, 78-81.	0.8	51
237	Adverse Cutaneous Reactions to Antimicrobials in Patients with Human Immunodeficiency Virus Infection. Dermatitis, 2007, 18, 8-25.	0.8	3
238	Sensitivity of Petrolatum and Aqueous Vehicles for Detecting Allergy to Imidazolidinylurea, Diazolidinylurea, and DMDM Hydantoin: A Retrospective Analysis from the North American Contact Dermatitis Group. Dermatitis, 2007, 18, 155-162.	0.8	19
239	Shoe Allergens: Retrospective Analysis of Cross-Sectional Data from the North American Contact Dermatitis Group, 2001-2004. Dermatitis, 2007, 18, 191-202.	0.8	69
240	Triclosan: An Update on Safety. Dermatitis, 2007, 18, 234-235.	0.8	2
241	Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facialÂseborrheic dermatitis. Journal of the American Academy of Dermatology, 2007, 57, 257-264.	0.6	68
242	Costs of pulse versus continuous terbinafine for onychomycosis. Journal of the American Academy of Dermatology, 2007, 56, 525-527.	0.6	7
243	Evaluation of prospectively collected presenting signs/symptoms of biopsy-proven melanoma, basal cell carcinoma, squamous cell carcinoma, and seborrheic keratosis in an elderly male population. Journal of the American Academy of Dermatology, 2007, 56, 739-747.	0.6	29
244	Contact dermatitis of the hands: Cross-sectional analyses of North American Contact Dermatitis Group Data, 1994-2004. Journal of the American Academy of Dermatology, 2007, 57, 301-314.	0.6	91
245	Allergic Contact Dermatitis: Another Adverse Effect of Over-the-counter Topical Hydrocortisone. Archives of Dermatology, 2007, 143, 1209.	1.7	14
246	Use of diagnostic tests by dermatologists, podiatrists and family practitioners in the United States: pilot data from a cross-sectional survey. Mycoses, 2007, 50, 463-469.	1.8	22
247	Naildex: pilot evaluation of an onychodystrophy severity instrument. Mycoses, 2007, 51, 070908013827006-???.	1.8	7
248	Reliability of self-reported willingness-to-pay and annual income in patients treated for toenail onychomycosis. British Journal of Dermatology, 2007, 156, 922-928.	1.4	20
249	NailQoL: a qualityâ€ofâ€life instrument for onychomycosis. International Journal of Dermatology, 2007, 46, 1279-1286.	0.5	38
250	Toenail onychomycosis: current and future treatment options. Dermatologic Therapy, 2007, 20, 31-46.	0.8	107
251	Digital Polarized Light Dermoscopy of Clinically Nonpigmented Dermal Nevi. Dermatologic Surgery, 2007, 33, 1120-1125.	0.4	7
252	Allergic Contact Dermatitis to Cosmetics. Dermatologic Clinics, 2006, 24, 215-232.	1.0	46

#	Article	IF	Citations
253	Pityriasis lichenoides and its subtypes. Journal of the American Academy of Dermatology, 2006, 55, 557-572.	0.6	188
254	A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis. Journal of the American Academy of Dermatology, 2006, 55, 40-46.	0.6	50
255	Cost-effectiveness of diagnostic tests for toenail onychomycosis: A repeated-measure, single-blinded, cross-sectional evaluation of 7 diagnostic tests. Journal of the American Academy of Dermatology, 2006, 55, 620-626.	0.6	7 5
256	Evaluating Costs for Onychomycosis Treatments. Journal of the American Podiatric Medical Association, 2006, 96, 38-52.	0.2	16
257	Dyshidrosis: Epidemiology, Clinical Characteristics, and Therapy. Dermatitis, 2006, 17, 165-181.	0.8	62
258	The Relationship of Vehicle and Concentration of Imidazolidinylurea, with Attention to Formaldehyde Allergy Status. Dermatitis, 2006, 17, 48-49.	0.8	6
259	Cutaneous Reactions to Transdermal Therapeutic Systems. Dermatitis, 2006, 17, 109-122.	0.8	39
260	Optimizing Reproducibility for Clinical Studies Involving Patch Testing and Application of Topical Preparations. Dermatitis, 2006, 17, 133-136.	0.8	2
261	Cross-reactions among Parabens, para-Phenylenediamine, and Benzocaine: A Retrospective Analysis of Patch Testing. Dermatitis, 2006, 17, 192-195.	0.8	23
262	Sunscreen Allergy: A Review of Epidemiology, Clinical Characteristics, and Responsible Allergens. Dermatitis, 2006, 17, 3-11.	0.8	84
263	Diagnosing and managing cutaneous pigmented lesions: Primary care physicians versus dermatologists. Journal of General Internal Medicine, 2006, 21, 678-682.	1.3	104
264	Allergic contact dermatitis from mercapto compounds. Dermatitis, 2006, 17, 56-70.	0.8	22
265	Allergenicity and cross-reactivity of coconut oil derivatives: A double-blind randomized controlled pilot study. Dermatitis, 2006, 17, 71-6.	0.8	17
266	A pilot evaluation of pulse itraconazole vs. terbinafine for treatment of Candida toenail onychomycosis*. International Journal of Dermatology, 2005, 44, 785-788.	0.5	14
267	Pulse versus continuous terbinafine for onychomycosis: A randomized, double-blind, controlled trial. Journal of the American Academy of Dermatology, 2005, 53, 578-584.	0.6	91
268	Prevention of onychomycosis reinfection for patients with complete cure of all 10 toenails: Results of a double-blind, placebo-controlled, pilot study of prophylactic miconazole powder 2%. Journal of the American Academy of Dermatology, 2005, 53, 717-720.	0.6	22
269	Parabens: A Review of Epidemiology, Structure, Allergenicity, and Hormonal Properties. Dermatitis, 2005, 16, 057.	0.8	21
270	Allergic Contact Dermatitis from Propolis. Dermatitis, 2005, 16, 209.	0.8	41

#	Article	IF	Citations
271	Benzyl Alcohol Allergy: Importance of Patch Testing with Personal Products. Dermatitis, 2005, 16, 203.	0.8	12
272	Methotrexate (MTX)-Induced Hepatotoxicity in Patients with Psoriasis. American Journal of Gastroenterology, 2005, 100, S136.	0.2	0
273	Parabens: a review of epidemiology, structure, allergenicity, and hormonal properties. Dermatitis, 2005, 16, 57-66; quiz 55-6.	0.8	75
274	Allergic contact dermatitis from propolis. Dermatitis, 2005, 16, 209-15.	0.8	66
275	Alcohol-Induced Application Site Erythema After Topical Immunomodulator Use and Its Inhibition by Aspirin. Archives of Dermatology, 2004, 140, 1014-5.	1.7	13
276	Diagnostic accuracy and appropriateness of management for pigmented lesions: primary care physicians and dermatologists. Journal of the American Academy of Dermatology, 2004, 50, P5.	0.6	0
277	Nail severity index (Naildex): burden of onychomycosis. Journal of the American Academy of Dermatology, 2004, 50, P91.	0.6	0
278	Pulse vs. continuous terbinafine for treatment of toenail onychomycosis: results of a double-blind controlled trial. Journal of the American Academy of Dermatology, 2004, 50, P101.	0.6	0
279	Cutaneous and Oral Eruption from Oral Exposure to Nickel in Dental Braces. Dermatitis, 2004, 15, 154.	0.8	46
280	Satisfaction with Onychomycosis Treatment. Journal of the American Podiatric Medical Association, 2003, 93, 373-379.	0.2	12
281	Latex Allergy. Skinmed, 2003, 2, 359-367.	0.0	11
282	Patch-Testing Practices of American Contact Dermatitis Society Members: A Cross-Sectional Survey. Dermatitis, 2003, 14, 005.	0.8	5
283	Pilot Evaluation of a Convenient and Cost-Effective Method of Patch Testing. Dermatitis, 2003, 14, 015.	0.8	2
284	Hand Dermatitis: A Review of Clinical Features, Therapeutic Options, and Long-Term Outcomes. Dermatitis, 2003, 14, 119.	0.8	26
285	Reimbursement for patch testing at academic centers: the Achilles' heel of academic contact dermatitis specialists. American Journal of Contact Dermatitis: Official Journal of the American Contact Dermatitis Society, 2003, 14, 215-6.	0.4	0
286	Calcinosis cutis as a complication of parenteral calcium gluconate therapy. Journal of Pediatrics, 2001, 138, 778.	0.9	18
287	Latex allergy. Journal of the American Academy of Dermatology, 1998, 39, 1-24.	0.6	123
288	American Academy of Dermatology's position paper on latex allergy. Journal of the American Academy of Dermatology, 1998, 39, 98-106.	0.6	82

#	Article	IF	CITATIONS
289	Contact Dermatitis to Essential Oils. Current Dermatology Reports, 0, , 1.	1.1	0